GlobeNewswire•5 days agoRadiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialRADX0.41%
GlobeNewswire•20 days agoEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsEYPT7.39%